<DOC>
	<DOCNO>NCT00255658</DOCNO>
	<brief_summary>This phase I trial study side effect best dose temsirolimus give together sorafenib treat patient unresectable metastatic solid tumor . Sorafenib temsirolimus may stop growth tumor cell block enzymes need cell growth . Sorafenib may also stop growth tumor cell block blood flow tumor . Giving sorafenib together temsirolimus may kill tumor cell .</brief_summary>
	<brief_title>Sorafenib Temsirolimus Treating Patients With Unresectable Metastatic Solid Tumors</brief_title>
	<detailed_description>PRIMARY OBJECTIVES : I . To characterize safety toxicity BAY 43-9006 ( sorafenib ) administer continuously twice daily oral route combination CCI-779 ( temsirolimus ) administer intravenously weekly advance solid malignancy . II . To determine maximum-tolerated dose ( MTD ) recommend dose phase II study ( RD ) regimen . III . To describe pharmacokinetic behavior BAY 43-9006 ( sorafenib ) CCI-779 ( temsirolimus ) combine . SECONDARY OBJECTIVES : I . To evaluate relationship pharmacokinetic ( PK ) parameter exposure drug effect biological surrogate proliferation , cell survival , differentiation angiogenesis peripheral blood mononuclear cell ( PBMCs ) tumor tissue tumor accessible biopsy . II . To analyze biologic effect BAY 43-9006 CCI-779 downstream target P13K/Akt/mTOR Raf signal pathway . III . To evaluate preliminary antitumor activity combination . OUTLINE : This open-label , dose-escalation study temsirolimus . Patients receive temsirolimus IV 30 minute day 1 , 8 , 15 , 22 . They also receive oral sorafenib* twice daily start day 8 course 1 . Treatment repeat every 4 week absence disease progression unacceptable toxicity . NOTE : *On day temsirolimus infusion , temsirolimus take concurrently morning dose sorafenib . Cohorts 3-6 patient receive escalate dos temsirolimus maximum tolerate dose ( MTD ) determine . The MTD define dose precede 2 3 2 6 patient experience dose-limiting toxicity . Up 12 patient treated MTD . After completion study treatment , patient follow 4 week .</detailed_description>
	<mesh_term>Sorafenib</mesh_term>
	<mesh_term>Everolimus</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<mesh_term>Niacinamide</mesh_term>
	<criteria>Patients must histologically confirm solid malignancy metastatic unresectable standard curative palliative measure exist longer effective ECOG performance status = &lt; ( Karnofsky &gt; = 60 % ) Predicted life expectancy great 12 week Leukocytes &gt; = 3,000 mcL Absolute neutrophil count &gt; = 1,500/mcL Hemoglobin &gt; = 9.0 g/dL Platelets &gt; = 100,000/mcL Fasting serum cholesterol = &lt; 350 mg/dL ( 9.0 mmol/L ) Total bilirubin within normal institutional limit AST ( SGOT ) /ALT ( SGPT ) = &lt; 2.5 x institutional upper limit normal ( ULN ) Creatinine within normal institutional limit OR creatinine clearance &gt; = 60 mL/min/1.73 m^2 patient creatinine level institutional normal Patients prophylactic anticoagulation therapy ( e.g. , lowdose warfarin ) eligible provide coagulation parameter level follow : INR ( International Normalized Ratio prothrombin time ) &lt; 1.1 x ULN Patients fulldose anticoagulant ( e.g. , warfarin ) PT INR &gt; 1.5 eligible provide follow criterion meet : The patient inrange INR ( usually 2 3 ) stable dose oral anticoagulant stable dose low molecular weight heparin The patient active bleed pathological condition carry high risk bleeding ( e.g. , tumor involve major vessel know varix ) Eligibility patient receive medication substance know affect potential affect activity pharmacokinetics BAY 439006 CCI779 determine follow review individual case Principal Investigator ; patient receive enzymeinducing antiepileptic drug ( EIAEDs ) phenytoin , phenobarbital , carbamazepine , rifampin , St. John 's wort ; patient must avoid grapefruit grapefruit juice Women childbearing potential men must agree use adequate contraception ( hormonal barrier method birth control ; abstinence ) prior study entry duration study participation ; woman become pregnant suspect pregnant participating study , inform treat physician immediately Ability understand willingness sign write informed consent document Complete supportive palliative care continue provide ameliorate sign symptom preexist may arise study interfere objective study ; use erythropoietin bisphosphonates permit Patients CNS metastasis eligible enrollment receive prior treatment ( include radiation therapy , stereotactic radiosurgery , surgical resection ) site ( ) CNS metastatic disease , requirement glucocorticoid , take anticonvulsant , overt evidence neurological deficit ; addition , radiologic scan perform within &lt; 14 day study entry show evidence disease progression peritumoral edema Patients chemotherapy radiotherapy within 4 week ( 6 week nitrosoureas mitomycin C ) prior enter study recover adverse event = &lt; grade 1 due agent administer 4 week earlier , exclude alopecia Patients receive investigational compound within past 28 day ; patient may receive investigational agent participate study History allergic reaction attribute compound similar chemical biologic composition BAY 439006 CCI779 Hypertension systolic blood pressure &gt; 140 mmHg diastolic pressure &gt; 90 mmHg ; however , patient wellcontrolled hypertension eligible Patients must evidence bleed diathesis coagulopathy ; patient PT INR &gt; 1.5 exclude , unless patient full dose warfarin Patients condition ( e.g. , gastrointestinal tract disease result inability take oral medication requirement IV alimentation , prior surgical procedure affect absorption , active peptic ulcer disease ) impair ability swallow pill exclude Uncontrolled intercurrent illness include , limited , uncontrolled hypertension , ongoing active infection , symptomatic congestive heart failure , unstable angina pectoris , cardiac arrhythmia , psychiatric illness/social situation would limit compliance study requirement Pregnant woman exclude study ; breastfeed discontinue mother treat either agent HIVpositive patient combination antiretroviral therapy ineligible Patients undergo major surgery sustain significant traumatic injury within 21 day prior treatment ineligible</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2013</verification_date>
</DOC>